Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

There may be potential clinical benefits to performing hereditary cancer risk assessments and multi-gene panel testing in patients with sarcoma.

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.

In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Although aldoxorubicin did not improve OS, the available evidence suggests that it is nevertheless superior to doxorubicin — particularly among patients with liposarcoma and leiomyosarcoma.

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.

Engagement Is Survival: My Take on ASCO 2017

Engagement Is Survival: My Take on ASCO 2017

Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Only 21% of patients underwent IGHV mutation-testing prior to initiating bendamustine plus rituximab therapy; 46% of tested patients were IGHV-mutated.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs